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PERANAN VARIASI-VARIASI GENETIK DAN PERUBAHAN-PERUBAHAN 
MOLEKULAR TERPILIH DI DALAM KANSER PANGKAL RAHIM YANG 
DICETUSKAN OLEH VIRUS PAPILOMA MANUSIA  
 
ABSTRAK 
 
Walaupun virus papilloma manusia (HPV) adalah faktor yang wajib bagi 
mencetuskan pembentukan kanser pangkal rahim, ia secara bersendirian adalah tidak 
cukup. Maklumat berkenaan peranan variasi-variasi genetik serta perubahan-perubahan 
molekular terpilih (dalam bentuk ekspresi gen, perubahan nombor salinan DNA dan 
kehilangan heterozigositi) di dalam kanser pangkal Rahim adalah tidak banyak diketahui 
dalam kalangan wanita di Malaysia pada masa ini. Maka, kajian ini dijalankan untuk 
mengisi jurang kesusasteraan ini. Bagi tujuan itu, hubung kait antara 12 polimorfisme 
genetik dalam sembilan gen yang terlibat dalam pelbagai rangkaian karsinogenik dengan 
risiko kanser pangkal rahim telah dinilai dalam 185 orang pesakit kanser pangkal rahim 
yang disahkan secara histopatologi dan 209 orang wanita kawalan tanpa kanser. Tahap 
ekspresi mRNA untuk sembilan gen tersebut, serta perubahan nombor salinan dan 
ketidakseimbangan alel keseluruhan genom, juga telah dikaji dalam 72 orang daripada 
jumlah subjek yang terlibat. Seterusnya, semua data yang diperolehi telah dibahagikan 
mengikut kumpulan etnik and subjenis HPV yang terlibat. Selain itu, data berkenaan 
perubahan-perubahan molekular tumor juga telah dibahagikan mengikut peringkat dan 
histopatologi kanser. Tambahan pula, hubung kait antara polimorfisme-polimorfisme 
genetik dengan tahap ekspresi gen-gen yang berkenaan juga telah dinilai. Hasil kajian ini 
menunjukkan bahawa 154 (83.2%) pesakit kanser pangkal rahim dan tiada (0.0%) 
xxiii 
 
wanita kawalan tanpa kanser adalah positif untuk jangkitan HPV. Antara subjek yang 
positif untuk jangkitan HPV, 141 (91.6%) dijangkiti oleh sejenis HPV sahaja 
(kebanyakannya HPV16, HPV18 dan HPV58) dan 13 (8.4%) yang selebihnya dijangkiti 
oleh dua jenis HPV pada masa yang sama (di mana HPV16 + HPV18 merupakan 
jangkitan yang paling biasa dijumpai). Hasil kajian ini juga menunjukkan bahawa 
selepas pelarasan terhadap faktor-faktor risiko kanser pangkal rahim yang diketahui, 
polimorfisme TNF c.-488G>A, CTLA4 c.49A>G, FAS c.-671A>G, MDM2 
c.14+309T>G and CCND1 c.723G>A menunjukkan hubungan yang signifikan secara 
statistik dengan risiko kanser pangkal rahim apabila dianalisis secara bersendirian. 
Selain itu, pemerhatian yang signifikan secara statistic juga telah dijumpai bagi beberapa 
gabungan antara polimorfisme CTLA4 c.-319C>T dengan polimorfisme TNF c.-418G>A, 
CDKN1A c.93C>A dan CCND1 c.*687C>G. Di samping itu, kajian ini juga 
menunjukkan bahawa PUM1, YWHAZ dan RPLP0 merupakan gen-gen rujukan yang 
diekspres dengan paling stabil di dalam kanser pangkal rahim, dan pelarasan tahap 
ekspresi sembilan gen calon tersebut terhadap gen-gen rujukan ini menunjukkan 
ketidakwujudan perbezaan tahap ekspresi relatif gen-gen calon itu di antara tisu kanser 
dan tisu tanpa kanser pangkal rahim. Walaupun begitu, kajian ini menjumpai hubung 
kait antara tahap ekspresi CTLA4 yang tinggi dengan alel varian polimorfisme CTLA4 
c.49A>G, dan tahap ekspresi FAS yang rendah dengan alel varian polimorfisme FAS c.-
671A>G. Kajian ini juga telah berjaya menyifatkan landskap perubahan nombor salinan 
dan kehilangan heterozigositi keseluruhan genom di dalam tisu kanser pangkal rahim, 
dan mengenal pasti bahawa lokus-lokus yang paling biasa menunjukan perubahan 
genomik secara berulang termasuk 3q21.3, 10q26.3 dan 5p15.33 (untuk penambahan 
nombor salinan), 11p11.12, Xp11.1 dan 12q11 (untuk kehilangan nombor salinan), dan 
xxiv 
 
Xq11.1, Xq22.3 dan 16p11.2 (untuk kehilangan heterozigositi). Kesimpulannya, kajian 
ini telah berjaya menentukan kelaziman dan pengagihan subjenis HPV dalam kalangan 
wanita di Malaysia, mengenal pasti beberapa polimorfisme genetik yang berhubung kait 
dengan risiko kanser pangkal rahim, dan menerangkan perubahan-perubahan molekular 
utama yang berlaku di dalam tisu kanser dan tisu tanpa kanser pesakit kanser pangkal 
rahim. Hasil kajian yang diperolehi ini dijangka akan mempunyai prospek yang penting 
dalam bidang perubatan perseorangan yang menjaminkan. 
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ROLES OF SELECTED GENETIC VARIATIONS AND MOLECULAR 
ALTERATIONS IN HUMAN PAPILLOMAVIRUS-MEDIATED CANCER OF 
UTERINE CERVIX 
 
ABSTRACT 
 
Although human papillomavirus (HPV) is essential for cervical carcinogenesis, it 
alone is insufficient to result in the malignant transformation of the cervix. Information 
on the roles of selected genetic variations as well as molecular alterations (in the forms 
of gene expression, DNA copy number alterations and loss of heterozygosity) in cervical 
cancer is currently lacking among Malaysian women. The present study was therefore 
undertaken to fill this gap of the literature. For this purpose, the associations of 12 
genetic polymorphisms in nine candidate genes involved in various carcinogenic 
pathways with cervical cancer risk were evaluated on 185 histopathologically confirmed 
cervical cancer patients and 209 cancer-free female controls. The mRNA expression 
levels of these nine candidate genes, as well as the genome-wide copy number 
alterations and allelic imbalances were also analyzed in cancerous and non-cancerous 
tissues of 72 of the subjects. All data obtained were subsequently stratified by ethnicity 
and HPV subtypes involved. In addition, data on tumor molecular alterations was also 
stratified by stages and histopathology of the cancer. Besides, the association between 
the genetic polymorphisms and their respective gene expression levels was investigated. 
It was demonstrated that 154 (83.2%) of the cervical cancer patients and none (0.0%) of 
the cancer-free female controls were positive for HPV infection. Among the HPV-
positive subjects, 141 (91.6%) had single-type HPV infections (of which HPV16, 
HPV18 and HPV58 predominated), while the remaining 13 (8.4%) were simultaneously 
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infected by two HPV types (with HPV16 + HPV18 being the most common multiple-
type infection). It was also observed in the present study that after adjustment to known 
risk factors of cervical cancer, TNF c.-488G>A, CTLA4 c.49A>G, FAS c.-671A>G, 
MDM2 c.14+309T>G and CCND1 c.723G>A polymorphisms showed statistically 
significant associations with the risk of the cancer when analyzed singly. In addition, 
statistically significant observations were noted for the several combinations of CTLA4 
c.-319C>T polymorphism with TNF c.-418G>A, CDKN1A c.93C>A and CCND1 
c.*687C>G polymorphisms. Apart from that, it was shown in the present study that 
PUM1, YWHAZ and RPLP0 were the most stably expressed reference genes in cervical 
cancer, and normalization of expression levels of the nine candidate genes against these 
reference genes showed no significant relative expression difference between cancerous 
and non-cancerous tissues of the cervix. However, an association was found between a 
higher CTLA4 expression and the variant allele of CTLA4 c.49A>G polymorphism, and 
between a lower FAS gene expression and the variant allele of FAS c.-671A>G 
polymorphism. The present study also successfully characterized the landscape of 
genome-wide copy number alterations and loss of heterozygosity in cervical cancer 
tissues, and observed that the most common loci with recurrent genomic alterations were 
3q21.3, 10q26.3 and 5p15.33 (for copy number gains), 11p11.12, Xp11.1 and 12q11 (for 
copy number losses), and Xq11.1, Xq22.3 and 16p11.2 (for losses of heterozygosity). In 
conclusion, the present study has successfully determined the prevalence and 
distribution of HPV types among Malaysian women, identified several host genetic 
polymorphisms associated with risk of cervical cancer, and identified some major 
molecular alterations which occurred in the cancerous and non-cancerous tissues of 
cervical cancer patients. These results have a potential prospect in the promising field of 
individualized preventive medicine. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Research background 
Cervical cancer is the seventh most common cancer worldwide and the fourth most 
common type of cancer among the female population (Ferlay et al., 2013). In Malaysia, 
the age-standardized rate of cervical cancer is 7.8 per 100,000 females, according to the 
most recent Malaysian National Cancer Registry Report (Omar & Tamin, 2011). The 
cancer develops slowly from a premalignant stage called cervical intraepithelial 
neoplasia (CIN), during which the cure rate is nearly 100% (Berget et al., 1991). 
Nevertheless, once CIN progresses into cervical cancer and spreads to distant organs, the 
average five-year survival rate of the patients drops drastically to 16.5% (National 
Cancer Institute, 2015). This implies that early detection and identification of cervical 
cancer is critical for appropriate management of the patients. 
 
 Currently, the most widely employed test for cervical cancer screening is the 
Papanicolaou test, more popularly known as the Pap test or Pap smear. However, a 
downside of this conventional screening test is its low sensitivity of approximately 37-
66% (Gyllensten et al., 2010; McCrory et al., 1999; Wright, 2007), which denotes that a 
considerable portion of patients is tested negative for cervical anomalies when 
premalignant or malignant dysplasia of the cervix is actually present. In addition, the 
lack of Pap screening resources has resulted in the high incidence of cervical cancer in 
developing countries (Kitchener et al., 2006). Therefore, there is a clear need for the 
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identification of potential biomarkers for early detection of individuals at risk of cervical 
cancer. 
 
 Over the past decades, it has become established that human papillomavirus 
(HPV) is the central etiologic agent for cervical carcinogenesis (Schiffman & 
Wentzensen, 2013). The viral DNA has been shown to be present in virtually all cervical 
carcinoma specimens examined worldwide (Walboomers et al., 1999), and persistent 
infection of HPV has been definitively linked to the development of the cancer 
(Schiffman & Wentzensen, 2013). However, the fact that most precancerous cervical 
lesions regress spontaneously and only a small proportion of HPV-infected women 
eventually develop cervical cancer suggests that HPV alone is not sufficient to 
contribute to cervical carcinogenesis. Other cofactors must therefore be present in 
conjunction with HPV infection for the progression of CIN into malignancy.  
 
 Several environmental and/or lifestyle factors have now been recognized as 
important cofactors for cervical carcinogenesis. Cigarette smoking, for example, has 
been shown to induce severe oxidative DNA damage especially in HPV-infected cells, 
thus increasing the susceptibility of smokers to cervical cancer (Moktar et al., 2011). In 
addition, multiparity and use of oral contraceptives may modulate the endogenous level 
of steroid hormones, which in turn affects the efficiency of immune response against 
HPV, thus facilitating cervical cancer development (Chung et al., 2010). Besides, in 
recent years, it has become more and more apparent that host genetic factors may affect 
the persistency of HPV infection, and could therefore serve as a non-modifiable risk 
factor for cervical cancer development and progression (Tan & Ankathil, 2015).  
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High penetrance genetic mutations can potentially confer a high lifetime risk of 
cancer among their carriers (Fletcher & Houlston, 2010). However, the search for high 
penetrance genetic mutations associated with cervical cancer has proven difficult and 
has been unsuccessful. Many researchers have thus shifted their attention to the 
identification of low penetrance single nucleotide polymorphisms (SNPs) associated 
with the cancer. It is thought that these low penetrance genetic polymorphisms could 
influence cervical cancer risk only modestly, but the magnitude of the risk association 
could be increased dramatically when several low penetrance genetic polymorphisms are 
combined (Fletcher & Houlston, 2010). In addition, since SNPs are highly prevalent in 
the general population, they may account for a greater population-attributable risk (PAR) 
of cervical cancer compared to high penetrance mutations (Tan & Ankathil, 2015).  
 
Among the large number of SNPs in the human genome, polymorphisms in 
genes which have been implicated to the complex mechanisms of carcinogenesis 
represent potential candidate risk markers for cervical cancer. SNPs of genes involved in 
mediating inflammatory and immune responses (e.g. TNF, IL4R, CTLA4 and CCR2), 
apoptosis and anti-apoptosis (e.g. TP53, FAS and MDM2), cell cycle regulation and 
DNA repair (e.g. CDKN1A and CCND1), among others, have been frequently 
investigated for their association with cervical cancer susceptibility (de Freitas et al., 
2012; Tan & Ankathil, 2015; Vineis et al., 2009; Wang et al., 2009b; Zhang et al., 
2014c), although inconsistent findings have been obtained in many studies. The 
inconsistency of the results obtained could be due to the different ethnic and 
geographical backgrounds of the study subjects included, or the different sample size 
and experimental approaches employed (Tan & Ankathil, 2015). There is currently a 
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paucity of data available regarding the association of candidate polymorphisms in the 
above genes with cervical cancer risk in Malaysian population. 
 
Besides, as carcinogenesis is a multistep process involving dysregulation of 
proto-oncogenes, tumor suppressor genes and other key genes involved in cell 
proliferation, inflammatory and immune responses, apoptosis, cell cycle regulation and 
DNA repair, disruption of gene expression is commonly observed in many cancers 
(Sadikovic et al., 2008; Sharma et al., 2010). Alteration in gene expression is thought to 
arise as a result of point mutations, gene rearrangements, gene amplifications, epigenetic 
events or other carcinogenesis-related genetic events (Pierotti et al., 2010; Sharma et al., 
2010). The resulting ectopic gene expression could in turn facilitate acquirement of 
cancer phenotypes by disrupting the downstream signaling pathways (Hanahan & 
Weinberg, 2000; Hanahan & Weinberg, 2011). If the expression level of a gene exhibits 
a consistent pattern of distinct cut-off between normal and cancerous tissues across a 
large number of specimens, it may potentially be used as a genetic marker for predicting 
disease prognosis or for molecular classification of cancer. Recent years have witnessed 
the identification of several potential genetic markers which are either upregulated (Xiao 
et al., 2014; Zhang et al., 2014b) or downregulated (Zhang et al., 2015) in cervical 
cancer. However, little is known about the expression levels of the aforementioned 
candidate genes (TNF, IL4R, CTLA4, TP53, FAS, MDM2, CDKN1A, CCR2 and CCND1) 
in cancerous and non-cancerous tissues of uterine cervix. Given the important role of 
these genes in various mechanisms of oncogenesis, evaluation of the differential gene 
expression of these genes in cervical cancer remains a promising avenue of research. 
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 Another molecular event which may arise during the process of carcinogenesis is 
somatic copy number alterations (CNAs), in which segments of DNA is present in non-
diploid copies. Somatic CNAs are arguably the most abundant genetic alteration in the 
cancer genome (Beroukhim et al., 2010; Zack et al., 2013), although its prevalence in 
cervical cancer has not been thoroughly investigated. The most apparent functional 
impact of somatic CNAs is the alteration of gene dosage, thereby resulting in over- or 
under-production of the gene products (Handsaker et al., 2015). In addition, somatic 
CNAs could result in the inactivation of tumor suppressor genes, hence facilitating 
malignant transformation. Considering the potential impact of somatic CNAs in 
oncogenesis, characterization of these molecular aberrations in cervical cancer could 
provide important insights into the etiology of cervical cancer. 
 
 Apart from that, loss of heterozygosity (LOH) represents another class of genetic 
alteration frequently observed in various cancers (Beroukhim et al., 2006). 
Conventionally, LOH has been thought to arise due to hemizygous deletion of one allele, 
thus resulting in a state of DNA copy number loss (Beroukhim et al., 2006). Recent 
studies, however, showed that LOH does not necessarily be associated with a net change 
in DNA copy number (Kumar et al., 2015; Melcher et al., 2011; O'Keefe et al., 2010; 
Stirewalt et al., 2014). In fact, this condition, termed copy-neutral LOH (CNLOH), is 
extremely ubiquitous in the human genome and may constitute as high as 70% of allelic 
imbalance events in human cancers. CNLOH is manifested when the remaining 
undeleted allele becomes duplicated. Since both resulting alleles are derived from a 
single parental chromosome, CNLOH is also sometimes referred to as acquired 
uniparental disomy (aUPD). CNLOH is potentially pathological if the wild type allele is 
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deleted and the mutant allele is duplicated. In addition, LOHs with copy number gains 
have also been reported, in which the remaining undeleted allele becomes amplified 
(Beroukhim et al., 2006; Kuga et al., 2008). So far, the contribution of LOH, CNLOH 
and LOH with copy number gains in modulating cervical cancer development is less 
well understood. Genome-wide screening for these genetic events in cervical cancer may 
serve as an important step for identification of key genomic regions harboring novel 
cancer-related genes. 
 
1.2 Rationale of the study 
HPV is by far the most important risk factor for cervical cancer. More than 100 HPV 
subtypes have been identified, but only several subtypes are classified as “high-risk” 
which are potentially carcinogenic to humans. Current HPV vaccines in Malaysia are 
available in bivalent (which targets on HPV16 and HPV18) and quadrivalent forms 
(which targets on HPV6, HPV11, HPV16 and HPV18) (Ministry of Health Malaysia, 
2011), although the United States Food and Drug Administration (U.S. F.D.A.) has 
recently approved a nonavalent (9-valent) form of the vaccine, which protects against 
HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52 and HPV58 
(Chatterjee 2014; U.S. F.D.A, 2014). Presently, the prevalence and type distribution of 
HPV in the Malaysian population are incompletely understood. Therefore, the present 
study assessed the prevalence and type distribution of HPV in cervical cancer, to help 
appraising the efficiency of the current vaccines in protecting against the disease.  
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 Apart from that, it is known that genetic polymorphisms typically influence 
cervical cancer risk in a population-specific manner. A number of candidate genetic 
polymorphisms have been investigated with regard to their association with cervical 
cancer risk in various other populations. These include the TNF c.-418G>A (rs361525), 
TNF c.-488G>A (rs1800629), IL4R c.1727A>G (rs1801275), CTLA4 c.49A>G 
(rs231775), CTLA4 c.-319C>T (rs5742909), TP53 c.215C>G (rs1042522), FAS            
c.-671A>G (rs1800682), MDM2 c.14+309T>G (rs2279744), CDKN1A c.93C>A 
(rs1801270), CCR2 c.190G>A (rs1799864), CCND1 c.723G>A (rs9344) and CCND1 
c.*687C>G (rs678653) polymorphisms. However, information is lacking regarding the 
allelic and genotypic distributions of these polymorphisms in the Malaysian population, 
as well as the contribution of these polymorphisms in modulating the susceptibility of 
HPV-mediated cervical cancer in Malaysia. This study addressed this issue employing a 
case-control analysis. 
 
Besides, it has now been widely recognized that disruption of gene expression 
represents an important feature of cancers. Among the many methods of gene expression 
profiling, reverse transcription-quantitative real-time PCR (RT-qPCR) is considered as 
the gold standard due to its simplicity, rapidity, sensitivity, specificity and 
reproducibility. However, reliability of RT-qPCR findings depends heavily on the 
appropriateness of its data normalization against reference genes whose expressions are 
constant across diverse biological conditions. There is no single „universal‟ reference 
gene which can be used for normalization of RT-qPCR data in all types of tissue, and the 
search for the optimal reference genes for a particular tissue type is critically important 
(Jacob et al., 2013; Kozera & Rapacz, 2013). There is currently a paucity of information 
8 
 
regarding the suitable reference genes to be used for normalization of RT-qPCR data in 
human cervical tissues. This study therefore screened a large panel of candidate 
reference genes to identify the optimal RT-qPCR reference genes for cancerous and non-
cancerous tissues of human uterine cervix. 
 
In addition, little is known about the expression changes of TNF, IL4R, CTLA4, 
TP53, FAS, MDM2, CDKN1A, CCR2 and CCND1 during the process of cervical 
carcinogenesis. Thus, this study investigated the mRNA expression of the above-
mentioned genes in cancerous and non-cancerous tissues of the uterine cervix and 
evaluated the difference of their expression between the two groups of the specimens, in 
order to determine whether dysregulation of these genes occurs during cervical cancer 
development. The present study also evaluated the usability of these genes as biomarkers 
of cervical cancer staging, by investigating whether a trend exists in the expression 
levels of the genes in increasing stages of cervical cancer. Besides, the influence of 
genetic polymorphisms on the expression of the respective genes was also investigated. 
 
Lastly, somatic copy number alterations (CNAs) and loss of heterozygosity 
(LOH) are known to be common events in many cancers. However, not much is known 
about the presence and genomic loci of CNAs and LOH in cervical cancer. Moreover, 
previous technologies which did not permit simultaneous screening of CNAs and LOH 
have failed to appreciate the significance of copy-neutral LOH (CNLOH) and LOH with 
accompanying copy number gain in oncogenesis. Hence, another aspect of this study 
was to employ the latest SNP array technology for concurrent profiling of CNAs and 
LOH in cancerous and non-cancerous tissues of the cervix.  
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1.3 Objectives 
 
General objective: 
To investigate the role of host genetic variations and tumor molecular alterations in 
HPV-mediated cancer of uterine cervix in Malaysian population 
 
Specific objectives: 
1. To determine the prevalence and type distribution of HPV in cervical cancer 
patients and cancer-free healthy female controls in Malaysia. 
2. To investigate the allele and genotype frequencies of selected polymorphisms in 
genes involved in mediating inflammatory and immune responses, apoptosis and 
anti-apoptosis, cell cycle regulation and DNA repair in cervical cancer patients 
and cancer-free healthy female controls in Malaysia, and to determine the 
association of these polymorphisms, either singly or in combinations, with 
cervical cancer risk. 
3. To determine the most stably expressed reference genes for normalization of 
reverse transcription quantitative real-time PCR (RT-qPCR) data in cancerous 
and non-cancerous tissues of human uterine cervix. 
4. To investigate the mRNA expression levels of TNF, IL4R, CTLA4, TP53, FAS, 
MDM2, CDKN1A, CCR2 and CCND1, and to assess the difference in gene 
expression of the above-mentioned genes, in cancerous and non-cancerous 
tissues of uterine cervix. 
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5. To determine the association between TNF, IL4R, CTLA4, TP53, FAS, MDM2, 
CDKN1A, CCR2 and CCND1 gene expression levels and their respective genetic 
polymorphisms. 
6. To characterize the genome-wide copy number alterations (CNAs) and allelic 
imbalances (LOH, CNLOH and LOH with copy number gains) present in 
cancerous and non-cancerous tissues of human uterine cervix. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Cancer 
Cancer refers to a group of diseases developed as a result of uncontrolled cell 
proliferation. This occurs when the normal biomolecular circuits for cell division and 
cell death have become dysregulated, leading to the formation of a mass of cells called 
tumor or neoplasm. Tumors can, however, be classified into benign or malignant, and 
only malignant tumors contribute to the development of cancer. Since every cell types 
have the possibility to become cancerous, more than 200 types of cancer have been 
identified to date (Pelengaris & Khan, 2006). These can be classified into four main 
forms, namely sarcomas, carcinomas, leukemia or lymphoma (Weinstock, 1984), in 
which the tumor originates from mesenchymal tissue, epithelial tissue, blood-forming 
tissues and immune cells, respectively. Of these, carcinoma is the most commonly seen 
form of cancer, and it represents more than 80% of all cancers (Liu, 2007). 
 
2.2 Hallmarks of cancer 
Hanahan and Weinberg (2000) have proposed that most, if not all, of human cancers 
manifest six essential physiological changes at the cellular level, which are commonly 
referred to as the core hallmarks of cancer. These changes are acquired during the 
multistep process of carcinogenesis, and each indicates that an anticancer defense 
mechanism within the cells has successfully been overcome. Extensive research in the 
field of oncology during the past decade has added two “emerging hallmarks” to the 
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above list, namely reprogramming of energy metabolism and evasion of immune 
destruction (Hanahan & Weinberg, 2011). Central to the acquisition of all the eight 
cancer hallmarks are two “enabling characteristics”, namely genome instability and 
mutation, as well as tumor-promoting inflammation (Hanahan & Weinberg, 2011). The 
core and emerging hallmarks of cancer are summarized in Table 2.1.  
 
Table 2.1: Core and emerging hallmarks of cancer (adapted from Hanahan & Weinberg, 
2000; Hanahan & Weinberg, 2011) 
Hallmarks of cancer Example of mechanism 
 
Core hallmarks: 
 
 
     Self-sufficiency in growth signals 
 
Activation of H-Ras oncogene 
 
     Insensitivity to anti-growth signals 
 
Loss of retinoblastoma suppressor 
 
     Evasion of apoptosis 
 
Production of insulin-like growth factor 
(IGF) survival factors 
 
     Limitless replicative potential 
 
Activation of telomerase 
 
     Sustained angiogenesis 
 
Production of vascular endothelial 
growth factor (VEGF)  inducer 
 
     Tissue invasion and metastasis 
 
Inactivation of E-cadherin 
 
Emerging hallmarks: 
 
  
     Reprogramming of energy metabolism Upregulation of glucose transporters  
 
     Avoidance of immune destruction 
 
Secretion of TGF-β or other 
immunosuppressive factors 
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2.3 Cervical cancer 
Cervical cancer is the malignant neoplasm occurring to the cells lining the cervix uteri. 
The cancer arises primarily from the squamocolumnar cell junction at an area termed the 
transformation zone. Cervical carcinoma typically develops slowly, beginning as a 
premalignant stage known histologically as cervical intraepithelial neoplasia (CIN). 
There are three grades of CIN, namely CIN 1, CIN 2 and CIN 3, which indicate mild, 
moderate and severe dysplasia, respectively (Richart, 1969). The premalignant cervical 
dysplasia can begin in any of the three grades. Cytologically, CIN 1 is known as low-
grade squamous intraepithelial lesion (LSIL), while CIN 2 and CIN 3 are known as 
high-grade squamous intraepithelial lesion (HSIL). CIN usually regresses spontaneously, 
but can sometimes progress into cervical cancer in a small proportion of patients (Ostör, 
1993; Schiffman & Wentzensen, 2013; Walboomers et al., 1999). 
 
Cervical cancers are histopathologically categorized according to the type of 
cells from which they are derived (International Agency for Research on Cancer, 2005). 
Cervical cancer that develops from squamous epithelial cells is called squamous cell 
carcinoma, while that which develops from columnar epithelial cells is known as 
adenocarcinoma. Less commonly, cervical cancers possess features of both squamous 
cell carcinoma and adenocarcinoma, in which case it is referred to as adenosquamous 
carcinoma. Squamous cell carcinoma represents the most common type of cervical 
cancer, with approximately 70-80% incidence rate (Vizcaino et al., 2000), as compared 
to around 20% incidence of adenocarcinoma (Schorge et al., 2004). Besides squamous 
cell carcinoma, adenocarcinoma and adenosquamous carcinoma, a rare subset of 
cervical cancer is manifested as neuroendocrine carcinoma, small cell carcinoma, clear 
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cell carcinoma, mixed Müllerian tumor, glassy cell carcinoma, among several other 
uncommon histopathological types (International Agency for Research on Cancer, 2005; 
Khalbuss et al., 2013). 
 
Globally, cervical cancer is the seventh most common type of cancer overall and 
the fourth most common cancer in women. Incidence data from GLOBOCAN database 
indicates that 527,624 new cervical cancer cases were diagnosed in year 2012 alone, and 
approximately 84.3% of these occur in developing countries (Ferlay et al., 2013). The 
mortality rate of cervical cancer, relative to its incidence rate, is approximately 50%. 
 
2.3.1 Staging of cervical cancer 
A number of systems have been employed for cervical cancer staging. Instead of being 
surgically-based as in the case of many other cancers, staging of cervical cancer is 
clinically-based, since many early studies have established that surgical staging of 
cervical cancers can complicate the downstream therapy processes (Delgado et al., 1978; 
Piver & Barlow, 1974; Wharton et al., 1977). 
 
The most widely used system for cervical cancer staging is the International 
Federation of Gynecology and Obstetrics (Fédération Internationale de Gynécologie et 
d'Obstétrique, or FIGO) system. Staging using the FIGO system relies principally on 
physical examinations, examination under anesthesia, colposcopy, cystoscopy, 
sigmoidoscopy, intravenous pyelogram and chest X-ray (Moore, 2006). The current 
FIGO staging system for cervical cancer (revised 2009) is shown in the Table 2.2 
(Pecorelli, 2009). Although discernment of carcinoma in situ from later stages of 
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cervical cancer is helpful for clinical management of patients, the FIGO staging system 
does not include a stage for the former. Thus, a Stage 0 is often informally used to 
denote carcinoma in situ. 
 
Table 2.2: FIGO staging system for cervical cancer (adapted from Pecorelli, 2009) 
Stage Description 
 
I 
 
 
       IA 
 
 
                 IA1 
 
 
                 IA2 
 
 
       IB 
 
 
                 IB1 
 
                 IB2 
 
 
The carcinoma is strictly confined to the cervix (extension to the corpus 
would be disregarded) 
 
Invasive carcinoma which can be diagnosed only by microscopy, with 
deepest invasion ≤5 mm and largest extension ≥7 mm 
 
Measured stromal invasion of ≤3.0 mm in depth and extension of ≥7.0 
mm 
 
Measured stromal invasion of >3.0 mm and not >5.0 mm with an 
extension of not >7.0 mm 
 
Clinically visible lesions limited to the cervix uteri or pre-clinical 
cancers greater than stage IA 
 
Clinically visible lesion ≤4.0 cm in greatest dimension 
 
Clinically visible lesion >4.0 cm in greatest dimension 
 
 
II 
 
      
       IIA 
 
                IIA1 
                 
IIA2 
 
       IIB 
 
 
Cervical carcinoma invades beyond the uterus, but not to the pelvic 
wall or to the lower third of the vagina 
 
Without parametrial invasion 
 
Clinically visible lesion ≤4.0 cm in greatest dimension 
 
Clinically visible lesion >4 cm in greatest dimension 
 
With obvious parametrial invasion 
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Table 2.2, continued 
Stage Description 
 
III 
 
 
       IIIA 
 
 
       IIIB 
 
 
The tumor extends to the pelvic wall and/or involves lower third of the 
vagina and/or causes hydronephrosis or non-functioning kidney 
 
Tumor involves lower third of the vagina, with no extension to the 
pelvic wall 
 
Extension to the pelvic wall and/or hydronephrosis or non-functioning 
kidney 
 
 
IV 
 
 
 
       IVA 
 
       IVB 
 
 
The carcinoma has extended beyond the true pelvis or has involved 
(biopsy proven) the mucosa of the bladder or rectum. A bullous edema, 
as such, does not permit a case to be allotted to Stage IV 
 
Spread of the growth to adjacent organs 
 
Spread to distant organs 
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2.3.2 Risk factor of cervical cancer: human papillomavirus (HPV) 
Human papillomavirus (HPV) (Figure 2.1) is the central etiologic agent in the 
development of cervical cancer. To date, more than 100 types of HPV have been 
identified, and about 40 of these can infect human genitalia (Bernard et al., 2010; de 
Villiers, 2001). The virus can be categorized into two categories, namely cutaneous and 
mucosotropic, with the latter being relevant to the development of cervical carcinoma. 
Mucosotropic HPV can further be classified into high and low risk groups, depending on 
their ability to immortalize human keratinocytes (de Villiers et al., 2004). The high risk 
group includes HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82 (Muñoz 
et al., 2003), and infection of any of these can result in cervical intraepithelial neoplasia, 
which can potentially progress into invasive cervical cancer. A total of 99.7% of cervical 
carcinoma samples have been tested positive for some of the above-mentioned HPV 
DNA (Walboomers et al., 1999). HPV16 and 18 predominate in cervical cancer, 
accounting for 50-60% and 10-20% of cervical cancer cases, respectively (Muñoz et al., 
2004). In fact, the International Agency for Research on Cancer (1995) has officially 
classified the two above-mentioned HPV types as Group 1, i.e. carcinogenic to humans. 
 
HPV possesses a circular, double-stranded DNA genome of approximately 8 kb 
in size, which encodes for six early genes (E1, E2, E4, E5, E6 and E7) and two late 
genes (L1 and L2) that are respectively expressed early and late in the HPV life cycle. 
There is also a long control region (LCR) in the HPV genome, which lies between the 
early and late gene regions that plays important regulatory roles in the replication and 
transcription of HPV genome (Figure 2.2). Upon infection, HPV genome typically exists 
as an episome in the nucleus of infected cells, and hijacks the host cell machinery for the 
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viral gene expression. The normal expression of E2 gene represses the expression of E6 
and E7, which are implicated in cervical neoplasia due to their abilities to inactivate p53 
and pRb tumor suppressor proteins, respectively (Figure 2.2) (Dyson et al., 1989; 
Scheffner et al., 1990; Tan & Ankathil, 2015; Werness et al., 1990). In cervical cancer 
and some cervical intraepithelial neoplasia, integration of HPV genome into host 
chromosome has been observed (Lehn et al., 1988). The integration results in the 
disruption of HPV E2 open reading frame (ORF), which abolishes the function of the E2 
protein (Tan & Ankathil, 2015). This causes the increased expression and stability of E6 
and E7 gene products, which can eventually lead to the immortalization and subsequent 
malignant transformation of the infected cells (Figure 2.2) (Münger et al., 1989; Tan & 
Ankathil, 2015; Villa & Schlegel, 1991). 
 
 
Figure 2.1: Structure of HPV (adapted from American Medical Association, 2012). 
 
Major capsid 
protein (L1) 
Viral nucleic 
acid (DNA) 
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Figure 2.2: The HPV genome. (A) The HPV genome comprises six early genes and two 
late genes, and a long control region in between. The encoded E2 protein serves as a 
transcriptional repressor for E6 and E7 genes. (B) Integration of HPV DNA into the host 
genome disrupts the E2 gene, allowing production of E6 and E7 proteins which 
respectively inhibit p53 and pRb tumor suppressor proteins (adapted from Tan & 
Ankathil, 2015). 
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2.4 Genetic predisposition to cancer 
The observations that cancers tend to cluster in families and segregate in a Mendelian 
fashion suggest that the predisposition of an individual to the development of cancer can 
be inherited. In cervical cancer, a familial aggregation of the disease has also been noted 
(Hemminki & Chen, 2006). Besides, it has been shown that the risk of developing 
cervical cancer was considerably higher in biologically-related first degree relatives of 
cervical carcinoma patients, compared to non-biologically-related relatives (Ahlbom et 
al., 1997). Furthermore, a recent large-scale study showed that monozygotic twins 
shared significantly more similar results in cervical smear test compared to dizygotic 
twins and other first-degree relatives (Vink et al., 2011). Based on these epidemiological 
studies, the genetic heritability of cervical smear abnormality and invasive cervical 
cancer has been proposed. 
 
Genetic predisposition of cancer can occur through the inheritance of highly 
penetrant germline mutations in key cancer susceptibility genes (Fletcher & Houlston, 
2010). The inheritance of such mutations is equivalent to the first hit of Knudson two-hit 
hypothesis of tumorigenesis (Knudson, 1971), thereby increasing an individual‟s 
lifetime risk of developing a cancer. Although numerous cancer susceptibility genes, 
such as BRCA1 and BRCA2 in hereditary breast and ovarian cancer (HBOC) syndrome, 
MMR genes in hereditary nonpolyposis colorectal cancer (HNPCC) and RB1 in 
hereditary retinoblastoma, have been characterized in other types of human cancer, 
identification of high penetrance mutations in cervical cancer has proven difficult. 
Considering this, and the fact that high penetrance mutations typically accounts for less 
than 10% of all human cancers, many genetic susceptibility studies of cancers have 
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shifted their focus to identification of low penetrance genetic polymorphisms over the 
past decades. 
 
In genetic epidemiological studies of cancers, low penetrance polymorphisms in 
genes involved in the complex mechanisms of oncogenesis have naturally become the 
potential candidates for investigation. These include the genes involved in inflammation, 
DNA repair, immune responses, detoxification of carcinogens, hormonal responses, 
among others. Although the cancer risk that can be conferred by these polymorphisms is 
relatively lower compared to the above-mentioned high penetrance mutations, the 
variant alleles of these genes frequently interact with environmental factors and 
predispose a significant portion of the population to the development of cancer. Many 
common SNPs in genes involved in various biological pathways, such as xenobiotic 
metabolism, DNA repair, inflammation, immune response, cell cycle regulation etcetera, 
have been shown to be associated with cancer. However, varying results have been 
obtained for the relationship between these SNPs and cancer risk, possibly due to the 
differences in experimental approaches and sample size used, as well as the ethnicity, 
genetic and geographical background of the subjects studied.  
 
2.5 TNF polymorphisms and cervical cancer  
Tumor necrosis factor (TNF) is a cytokine encoded by the TNF gene on chromosomal 
locus of 6p21.3 in human. The gene spans a region of approximately 2.7 kb, and 
comprises 4 exons, with the last exon encoding for the majority of the protein (Nedwin 
et al., 1985). Together with two lymphotoxin genes (LTA and LTB; Browning et al., 
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1993) and Lst-1 gene (Holzinger et al. 1995), TNF occurs within the major 
histocompatibility complex (MHC) class III region in the TNF gene cluster. 
 
TNF is initially produced as a 26 kDa transmembrane protein, which is 
composed of 212 amino acids arranged in stable homotrimers (Kriegler et al., 1988; 
Tang et al., 1996). The mature soluble cytokine, which is 17 kDa in size and 185 amino 
acids long, is produced following proteolytic cleavage of the initial transmembrane 
protein by TNF-alpha converting enzyme (TACE) (Black et al., 1997). The secreted 
protein functions in homotrimeric structure and is unstable below the nanomolar range 
as it tends to dissociate into monomeric subunits at low concentrations (Corti et al., 
1992). 
 
TNF can potentially play a role in the progression and development of cancer, as 
ectopic expression of the TNF has been observed in certain cancer cells (Locksley et al., 
2001). The role of TNF in cancer development is further envisaged by considering the 
fact that it is one of the most crucial cytokine involved in the induction of inflammation, 
a process which allows various bioactive molecules such as growth factors, survival 
factors, proangiogenic factors, extracellular matrix-modifying enzymes and inductive 
signals to be supplied to the tumor microenvironments (Hanahan & Weinberg, 2011). 
Moreover, inflammatory cells have been shown to release reactive oxygen species and 
other mutagenic chemicals which can promote the malignancy of their nearby cancer 
cells (Grivennikov et al., 2010). In addition, TNF have been shown to be able to 
promote angiogenesis either directly by stimulating the proliferation of endothelial cells, 
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or indirectly by modulating the expression of various proangiogenic factors (Leek et al., 
1998). 
 
Aberrant expression of TNF could result in an increased risk of cervical cancer. 
Promoter region of the TNF gene contains a number of regulatory sequences which can 
serve as the binding sites of transcriptional activators or repressors and lead to either an 
increase or a decrease expression level of the gene. Polymorphisms in the promoter 
region of the gene could disrupt these regulatory sequences and could thus influence the 
level of TNF expression. Certain TNF promoter polymorphisms, such as the well-studied 
c.-418G>A polymorphism (rs361525, previously known as the -238G>A polymorphism) 
and c.-488G>A polymorphism (rs1800629, previously known as the -308G>A 
polymorphism), have been associated with the risk of developing cancers, although the 
results obtained in many studies are inconsistent. The inconsistency appeared to occur in 
a population-specific manner. For example, a genetic susceptibility study on the Korean 
population revealed a significant association between the c.-418A allele and a lower 
predisposition risk of cervical cancer, and lack of association between the c.-488G>A 
polymorphism and the malignancy (Jang et al., 2001). On the contrary, Zuo et al. (2011) 
reported no association between c.-418G>A polymorphism and cervical cancer risk 
among Southwest Chinese population, while Duarte et al. (2005) observed that the               
c.-488A genotype of TNF could confer a higher risk of developing cervical cancer 
among Portuguese population. Despite this, a meta-analysis of 13 studies which 
involved a total of 3,294 cases and 3,468 controls showed that the c.-418A allele was 
significantly associated with a decreased risk of cervical cancer, while the c.-488G>A 
polymorphism was associated with an increased cervical cancer risk only among 
24 
 
Caucasians and Africans, but not among Asians or subjects with mixed ethnicities (Pan 
et al., 2012). No study has been performed to investigate the association between the 
polymorphisms and cervical cancer risk in the Malaysian population. 
 
2.6 Interleukin-4 receptor (IL4R) and cervical cancer 
Interleukin-4 receptor (IL4R) is a transmembrane cytokine receptor found in between 50 
and 5,000 units on the surface of most cell types (Nelms et al., 1999; Zamorano et al., 
2003). There are two major forms of IL4R, namely the type I and the type II receptors, 
which are predominantly expressed in immune and cancer cells, respectively (Murata et 
al., 1998). Both types of receptors contain an alpha chain (IL4Rα), which is a 
polypeptide belonging to the hematopoietin receptor superfamily that is encoded by the 
IL4R gene located on chromosome 16p12.1 in humans. 
 
Upon IL4 binding, IL4Rα in type I receptors heterodimerizes with the gamma 
chain of IL2 receptor (IL2Rγ), while that in type II receptors forms a heterodimer with 
the alpha-1 chain of IL13 receptor (IL13Rα1) (Orchansky et al., 1999). IL2Rγ and          
IL13Rα1 are encoded by IL2RG on chromosome Xq13.1 and IL13RA on chromosome 
Xq24, respectively. In certain types of cells, type III IL4 receptors, which contain all the 
three above-mentioned chains, are present, although IL4 was found to be in association 
with only two of the chains at any given time following heteromerization (Murata et al., 
1998). Heterodimerization between IL4Rα and IL2Rγ and/or IL13Rα1 is necessary for 
the activation of the Janus family of tyrosine kinases (JAK), which brings about the 
downstream signaling cascades (Ihle, 1995).  
 
